| Active substance | Idelalisib |
| Holder | Cromsource on behalf of Gilead Sciences Benelux |
| Status | Closed |
| Indication | Relapsed chronic lymphocytic leukemia in adult patients who cannot be treated with chemotherapy due to refractoriness or comorbidities |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 17/07/2015 |
Zydelig®
Last updated on 10/09/2024